NCT01366144 2026-04-13
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
79 trialsNCT05420948 2026-04-09
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
University of Chicago
Phase 2 Suspended
NCT03485209 2026-04-07
innovaTV 207
Seagen Inc.
Phase 2 Active not recruiting
NCT06110195 2026-03-31
Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer
University of Chicago
Phase 1 Terminated
NCT04722523 2026-03-30
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT05108870 2026-03-25
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
University of Chicago
Phase 1/2 Not yet recruiting
NCT04858269 2026-03-24
First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients
Wake Forest University Health Sciences
Phase 2 Recruiting
NCT01612351 2026-03-17
Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT07209189 2026-03-09
(NeoScorch HN)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT04222972 2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3 Terminated
NCT07065630 2026-03-04
Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer
University of Chicago
Phase 2 Recruiting
NCT05544136 2026-02-27
A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07353723 2026-01-20
Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer
Tang-Du Hospital
Phase 2 Recruiting
NCT02270814 2025-12-30
CACTUX
Washington University School of Medicine
Phase 2 Active not recruiting
NCT01154920 2025-12-17
Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03358472 2025-12-03
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Incyte Corporation
Phase 3 Completed
NCT04954599 2025-10-07
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Maastricht University Medical Center
Phase 1/2 Recruiting
NCT04675333 2025-08-03
Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
ALX Oncology Inc.
Phase 2 Active not recruiting
NCT02358031 2025-07-18
MK-3475-048
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT06940180 2025-06-26
Toripalimab With Chemotherapy for Sinus Cancer
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT05726370 2025-06-22
Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT05388773 2025-06-19
Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
University of Pittsburgh
Phase 2 Recruiting
NCT05704985 2025-05-29
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
Phase 1 Active not recruiting
NCT04999761 2024-09-25
AB122 Platform Study
Taiho Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT06366945 2024-04-16
Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Not yet recruiting
NCT05358548 2024-04-10
ATATcH Alternating Treatment Plans for Advanced Cancer
Rutgers, The State University of New Jersey
Phase 2 Recruiting
NCT01437449 2024-01-30
Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Stanford University
Phase 2 Completed
NCT01172470 2023-11-29
Phase II Trial of Pemetrexed-Based Induction Chemotherapy Followed by Concomitant Chemoradiotherapy in Previously Irradiated Head and Neck Cancer Patients
University of Chicago
Phase 2 Completed
NCT02897375 2023-10-10
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
Emory University
Phase 1 Completed
NCT06062602 2023-10-06
PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC
Presage Biosciences
Phase EARLY_PHASE1 Completed
NCT02741570 2023-09-21
CheckMate 651
Bristol-Myers Squibb
Phase 3 Completed
NCT00079079 2023-08-04
Cisplatin or Carboplatin Combined With Gemcitabine in Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor
Canadian Cancer Trials Group
Phase 2 Completed
NCT04572100 2023-07-07
Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer
University of Chicago
Phase 1 Completed
NCT00089297 2023-06-29
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT02578641 2023-06-28
VANCE
Tessa Therapeutics
Phase 3 Completed
NCT02760667 2023-06-27
Induction Chemotherapy Followed by Surgery for Locally Advanced Head and Neck Cancer
George Washington University
Phase 2 Unknown
NCT00003206 2023-06-15
Carboplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00014118 2023-06-15
Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Larynx or Oropharynx Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00997906 2022-09-29
Cisplatin and RT With or Without Gemcitabine, Carboplatin, and Paclitaxel in Treating Patients With Locally Advanced NPC
National Cancer Centre, Singapore
Phase 2/3 Unknown
NCT01716195 2021-02-26
Induction Chemotherapy Followed by Chemoradiotherapy for Head and Neck Cancer
University of California, Davis
Phase 2 Completed
NCT01412229 2020-11-23
Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT01020864 2020-11-02
CECAVI
Odense University Hospital
Phase 2 Withdrawn
NCT02124707 2020-08-12
Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT03342352 2019-12-20
Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)
Incyte Corporation
Phase 3 Withdrawn
NCT01063075 2019-09-26
A Study in Advanced Solid Tumors
Eli Lilly and Company
Phase 2 Completed
NCT01081041 2019-09-25
A Study in Head and Neck Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00343083 2019-08-19
Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)
University of Maryland, Baltimore
Phase 2 Completed
NCT01016769 2019-06-26
Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT03386838 2019-04-18
An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck
Bristol-Myers Squibb
Phase 3 Withdrawn
NCT02633800 2019-01-07
Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )
Daiichi Sankyo
Phase 2 Terminated